At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 516 enrolled
Drug / intervention
fesoterodine fumaratedrug
Likely dose
fesoterodine fumarate 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-Week, Multicenter, Open-Label, Single-Arm Study To Evaluate The Effects Of Fesoterodine On Treatment Satisfaction And Symptom Relief In Overactive Bladder Patients.
In Brief
A Phase 3 clinical trial evaluating fesoterodine fumarate for Overactive Bladder. Completed, enrolled 516 participants across 60 sites in 9 countries.
Detailed Summary
To evaluate the effect of fesoterodine on patient satisfaction and overactive bladder (OAB) symptom relief in OAB patients who were dissatisfied with their prior therapy with tolterodine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
CountriesBelgium, Costa Rica, Czechia, Germany, Poland, Slovakia, South Korea, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedJan 2007
Primary CompletionOct 2007
TodayJul 2026
First PostedJan 22, 2007
Enrollment StartJan 1, 2007
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 19.4 years ago
Interventions
fesoterodine fumaratedrug
12 weeks of study treatment: Subjects received fesoterodine tablets 4 mg once daily for 4 weeks; thereafter, daily dosage was maintained at 4 mg or increased to 8 mg based on subject's and physician's subjective assessment of efficacy and tolerability.